Eris Lifesciences 미래 성장
Future 기준 확인 4/6
Eris Lifesciences (는) 각각 연간 30.7% 및 16.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 30.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.8% 로 예상됩니다.
주요 정보
30.7%
수익 성장률
30.7%
EPS 성장률
| Pharmaceuticals 수익 성장 | 18.3% |
| 매출 성장률 | 16.2% |
| 향후 자기자본 수익률 | 18.8% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 01 Nov 2024 |
최근 미래 성장 업데이트
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Recent updates
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 3/31/2027 | 38,502 | 7,188 | 9,355 | 11,113 | 9 |
| 3/31/2026 | 34,067 | 5,453 | 8,404 | 9,875 | 9 |
| 3/31/2025 | 30,061 | 3,807 | -11,008 | 6,931 | 9 |
| 9/30/2024 | 24,853 | 3,485 | 5,931 | 7,068 | N/A |
| 6/30/2024 | 22,469 | 3,803 | N/A | N/A | N/A |
| 3/31/2024 | 19,913 | 3,920 | 3,568 | 4,860 | N/A |
| 12/31/2023 | 18,406 | 3,864 | N/A | N/A | N/A |
| 9/30/2023 | 17,750 | 3,856 | -3,302 | 4,446 | N/A |
| 6/30/2023 | 17,298 | 3,824 | N/A | N/A | N/A |
| 3/31/2023 | 16,618 | 3,822 | -5,497 | 2,917 | N/A |
| 12/31/2022 | 15,663 | 3,970 | N/A | N/A | N/A |
| 9/30/2022 | 14,766 | 3,959 | 419 | 2,844 | N/A |
| 6/30/2022 | 13,746 | 3,940 | N/A | N/A | N/A |
| 3/31/2022 | 13,262 | 4,061 | 2,572 | 3,783 | N/A |
| 12/31/2021 | 12,993 | 3,941 | N/A | N/A | N/A |
| 9/30/2021 | 12,763 | 3,834 | 4,058 | 4,428 | N/A |
| 6/30/2021 | 12,482 | 3,728 | N/A | N/A | N/A |
| 3/31/2021 | 11,926 | 3,551 | 3,496 | 3,754 | N/A |
| 12/31/2020 | 11,625 | 3,432 | N/A | N/A | N/A |
| 9/30/2020 | 11,192 | 3,165 | 1,211 | 2,724 | N/A |
| 6/30/2020 | 10,744 | 3,015 | N/A | N/A | N/A |
| 3/31/2020 | 10,582 | 2,965 | 1,199 | 2,712 | N/A |
| 12/31/2019 | 10,252 | 2,943 | N/A | N/A | N/A |
| 9/30/2019 | 10,119 | 3,110 | 2,219 | 2,599 | N/A |
| 6/30/2019 | 9,920 | 3,036 | N/A | N/A | N/A |
| 3/31/2019 | 9,672 | 2,908 | 1,850 | 2,230 | N/A |
| 12/31/2018 | 9,851 | 2,925 | N/A | N/A | N/A |
| 9/30/2018 | 9,442 | 2,870 | N/A | N/A | N/A |
| 6/30/2018 | 9,212 | 2,945 | N/A | N/A | N/A |
| 3/31/2018 | 8,196 | 2,941 | N/A | 2,346 | N/A |
| 12/31/2017 | 8,026 | 2,800 | N/A | N/A | N/A |
| 9/30/2017 | 7,781 | 2,735 | N/A | N/A | N/A |
| 6/30/2017 | 7,277 | 2,505 | N/A | N/A | N/A |
| 3/31/2017 | 7,205 | 2,468 | N/A | 2,002 | N/A |
| 3/31/2016 | 5,967 | 1,112 | N/A | 1,315 | N/A |
| 3/31/2015 | 5,456 | 892 | N/A | 901 | N/A |
| 3/31/2014 | 5,088 | 704 | N/A | 896 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: ERIS 의 연간 예상 수익 증가율( 30.7% )이 saving rate( 6.7% 보다 높습니다. ).
수익 vs 시장: ERIS 의 연간 수익( 30.7% ) Indian 시장( 18.1% 보다 빠르게 성장할 것으로 예상됩니다. 18.1% 연간).
고성장 수익: ERIS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: ERIS 의 수익(연간 16.2% ) Indian 시장( 10.2% 보다 빠르게 성장할 것으로 예상됩니다. 10.2% 연간).
고성장 수익: ERIS 의 수익(연간 16.2% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: ERIS 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 18.8 %).